Purpose Treatment of large-segmental bone defects still is a challenge in clinical routine. Application of gene-activated matrices (GAMs) based on fibrin, bone morphogenic protein (BMP) 2/7 plasmids and nonviral transfection reagents (cationic polymers) could be an innovative treatment strategy to overcome this problem. The aim of this study was to determine the therapeutic efficacy of fibrin GAMs with or without additional transfection reagents for BMP2 and 7 plasmid codelivery in a femur nonunion rat model. Methods In this experimental study, a critical-sized femoral defect was created in 27 rats. At four weeks after the surgery, animals were separated into four groups and underwent a second operation. Fibrin clots containing BMP2/7 plasmids with and without cationic polymer were implanted into the femoral defect. Fibrin clots containing recombinant human (rh) BMP2 served as positive and clots without supplement as negative controls. Results At eight weeks, animals that received GAMs containing the cationic polymer and BMP2/7 plasmids showed decreased bone volume compared with animals treated with GAMs and BMP2/7 only. Application of BMP2/7 plasmids in fibrin GAMs without cationic polymer led to variable results. Animals that received rhBMP2 protein showed increased bone volume, and osseous unions were achieved in two of six animals. Conclusions Cationic polymers decrease therapeutic efficiency of fibrin GAM-based BMP2/7 plasmid codelivery in bone regeneration. Nonviral gene transfer of BMP2/7 plasmids needs alternative promoters (e.g. by sonoporation, electroporation) to produce beneficial clinical effects.
Introduction
Treatment of large-segmental bone defects remains a challenge in clinical routine. In recent years the US Food and Drug Administration (FDA) approved the clinical use of recombinant human bone morphogenic proteins (rhBMP)2 and 7 for special indications, providing an innovative tool for treating substantial bone defects [1] . Despite encouraging results in clinical routine, therapy costs remain high, and the local use of highly increased BMP concentrations raises safety concerns [2] . An alternative strategy is the delivery of BMP transgenes instead of recombinant growth factors in order to generate a local, sustained release of host-cell-produced, highly bioactive growth factors [3] [4] [5] [6] . Recent experimental data showed a synergistic effect of BMP2/7 therapeutic gene codelivery [7] [8] [9] . This promises to increase therapeutic efficiency in upcoming clinical studies. Such gene-therapy approaches could increase the efficiency of BMPs and reduce costs and potential side effects. Viral delivery of DNA vectors to the target tissue was shown to be highly effective but could result in a fatal host immune response host [10, 11] . In contrast, nonviral gene transfer using plasmids is regarded as a relatively safe but inefficient strategy [12, 13] .
Several strategies have been developed to overcome barriers to nonviral gene delivery and to enhance transfection efficacies [14, 15] . The use of cationic polymers or lipoplexes and other reagents for nonviral gene delivery is a wellestablished method that can significantly increase transfection efficacies in vitro and in vivo [16] [17] [18] . In recent years, several studies succeeded in increasing passive gene transfer by lipofection-or cationic-polymer-based gene delivery in animal models: Critical-sized mandibular defects in rats were successfully treated by liposome-mediated gene transfer of BMP2 in an ex vivo setting [19] . In vivo experiments showed increased bone formation and osseointegration when using liposomal BMP2 vectors in calvaria defects in pigs [20] . Using fibrin-based gene-activated matrices (GAMs) is another strategy that showed promising results in promoting passive gene transfer [21] . One in vivo study assessed wound healing in an epigastric flap rat model. Animals treated with vascular endothelial growth factor (VEGF) plasmids and GAMs consisting of fibrin and lipofectamine showed increased vascularisation and flap survival compared with the control groups [22] . To date, there is no study focusing on the effects of transfection-reagent-enhanced in vivo codelivery of BMP2/7 plasmids in GAMs in a segmental bone-defect model. Therefore, the aim of this study was to determine the therapeutic efficacy of fibrin GAMs with or without additional poly(hydroxyalkylene)imine (PEI) cationic transfection reagents for BMP2/7 plasmid codelivery in a femur nonunion rat model.
Materials and methods

BMP2 and BMP7 plasmids
Preparation and in vitro testing of BMP2/7 plasmids are described elsewhere [23] . The plasmids were amplified in Escherichia coli TOP10 (Life Technologies Ltd, Paisely, UK) and isolated as endotoxin-free maxipreps using the EndoFree Plasmid Maxi or Giga kits (Quiagen GmbH, Hilden, Germany. For plasmid maps, see Fig. 1 .
Experimental protocol
All experiments performed in this study were approved by the Animal Protocol Review Board of the City Government of Vienna. Animals were maintained and treated in accordance with the requirements of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (DHHS NIH 86-23, 1985) . We used a critical-sized defect model in rat femurs that was previously validated and included biomechanical testing and micro-computed tomography (CT) analysis [24] . We studied male Sprague-Dawley rats at an age of 20-24 weeks and weighing at least 350 g. The animals were randomised and separated into four groups (n = 6-9). All animals underwent surgery to create a standardised critical-sized defect (3.8 mm) of the right femur. A silicone spacer was placed into the defect to avoid formation of vascularised scar tissue. At four weeks, all animals underwent a second surgery. The silicone spacer was removed. The defect was filled with fibrin clots (160 μl), which served as GAM for all groups. Beneficial effects using fibrin as GAM for gene delivery was extensively studied and previously published [21, 22] .
The fibrin sealant (Tisseel®, Baxter AG, Vienna, Austria) was prepared according to the manufacturer's recommendations: 31.25 μl of fibrinogen, 31.25 μl of thrombin (c=400 IU/ml) and supplements (rhBMP2, BMP2/7 plasmids, cationic polymer) were mixed in an Eppendorf tube cap under sterile conditions. Saline was added up to a volume of 160 μl. The fibrin clot was allowed to solidify at 37°C for five minutes before implantation.
In the first group (FIBRIN, n=6) animals received a fibrin clot without supplement. In the second group (rhBMP2, n=6) animals received a fibrin clot containing 10 μg recombinant human BMP2 (InductOS®, Pfizer, Vienna, Austria). In the third group (BMP2/7, n=9), animals received a fibrin clot containing 20 μg BMP2 and 20 μg BMP7 plasmid vectors. In the fourth group (PEI_BMP2/7, n=6), animals received a fibrin clot containing 20 μg BMP2 plasmids, 20 μg BMP7 plasmids and 40 μl poly(hydroxyalkylene)imine (Turbofect®, Thermo Scientific Inc., Vilnius, Lithuania [25] ). At eight weeks, all animals were sacrificed, and union rate, bone volume and bone density was determined.
Surgical procedure
Animals were anaesthetised by intramuscular injection of ketamine hydrochloride (110 mg/kg body weight; Ketamidor, Richter Pharma, Austria) and xylazine hydrochloride (12 mg/kg body weight; Rompun, Bayer Healthcare, Germany). Each rat was placed on a thermostatic heating plate in a lateral decubitus position. A lateral approach was used to expose the femoral shaft. A 2-mm, five-hole Arbeitsgemeinschaft für Osteosynthesefragen (AO) titanium plate was fixed onto the anterolateral surface of the femur using four AO cortical screws (Synthes, Switzerland). A 3.8-mm segmental bone defect was created by double osteotomy in the femur's midshaft using a reciprocating saw (CORE, Stryker Instruments, USA) under guidance of a template. To simulate a delayed union, the femoral gap was filled with a 3.8-mm silicone spacer, which was firmly sutured onto the plate. The wound was closed in two layers, and animals were allowed free movement. Analgaesia was postoperatively provided by subcutaneous administration of meloxicam (0.15 mg/kg body weight; Metacam, Boehringer Ingelheim, Germany) for four days. At four weeks, all animals underwent a second intervention. The segmental bone defect was exposed through a small skin incision under anaesthesia. The silicone spacer was removed, and the proximal and distal femoral bony edges were debrided using a burr (CORE Micro Drill, Stryker) under constant irrigation with physiologic saline solution. After creating bleeding bony surfaces, we applied fibrin clots with or without supplements according the experimental protocol. The wound was closed in layers. At eight weeks, anaesthetised animals were sacrificed and their right femurs explanted for further measurements. The surrounding soft tissue was removed, and specimens were fixed in 4 % neutral-buffered formalin for further radiological and histological assessments.
Imaging
For assessment of union rate and bone volume, femora were explanted and the titanium plate and screws replaced by a synthetic radiolucent device. The bone was scanned using a microtomographic system (μCT 20; Scanco Medical, Zurich, Switzerland) between 2 mm proximal and distal to the defect. A 3D image was reconstructed using 100 horizontal micro-CT slide images 30-μm thick, giving a resolution of 20 μm. Bone tissue was isolated using an automatic threshold procedure. The callus crosssectional area was assessed in an interfragmentary horizontal slice.
In a first step, all rat femurs were classified. Specimens exhibiting a visible bony bridge that increased 30 % of the total cross-sectional defect area were defined as unions. Bony bridges <30 % were defined as narrow unions. Specimens without new bone formation in the defect area were classified as oligotrophic or atrophic nonunions according to Weber and Cech [26] . In a second step, we performed a quantitative analysis of newly formed bone within the defect area. Bone volume is expressed in mm 3 per defect.
Histology
After completing the radiological measurements, specimens were fixed in 4 % neutral-buffered formalin for 48 hours and rinsed in tap water overnight. After that, specimens were submitted to a quick decalcification with an agent containing 14 % hydrochloric acid (New decalc®, Medite, Burgdorf, Germany) and subsequently rinsed with running tap water overnight. Decalcified bone samples were dehydrated and embedded in paraffin, and 4-μm sections were cut on a rotary microtome. The paraffin sections were deparaffinised in xylene, rehydrated in graded alcohols and stained with hematoxylin and eosin (H&E).
Statistics
All data (except the percentage of bone union) are presented as median±interquartile range (IQR). Statistical analysis was performed using a standard software package (Graph Pad Prism, Graph Pad Software Inc., CA, USA). Normal distribution of data was tested using the Kolmogorov-Smirnov test. Groups were compared using one-way analysis of variance (ANOVA); post test was performed using the Tukey's multiple comparison test and P values <0.05 were considered statistically significant.
Results
Union rate
Union rate was assessed eight weeks after creation of the defect and four weeks after implantation of fibrin clots containing plasmids with/without cationic polymer. Unions were classified according to Weber and Cech [26] . Osseous unions were found in two of six animals in the rhBMP2 group; further, two animals in this group showed narrow unions. Oligotrophic nonunions were found in one of six animals in the FIBRIN group, three of nine in the BMP2/7 group, and two of six in the rhBMP2 group (Fig. 2) .
Bone volume
Bone volume within the critical-size defect was determined in all 27 treated rat femurs (Fig. 3) . Animals in the PEI_BMP2/7 group showed significantly decreased bone volume compared with the rhBMP2 (p<0.01) and the BMP2/7 (p<0.05) groups. Animals in the rhBMP2 group showed significantly increased bone volume compared with the FIBRIN (p <0.05) and PEI_BMP2/7 groups (p<0.01). There was no significant difference between rhBMP2 and BMP2/7 groups.
Histological findings
Rat femur sections were subjected to H&E staining to analyse tissue characteristics and bone quality. Representative histological specimens of each group are presented shown in Fig. 4a-d) . Samples in the FIBRIN group showed tight fibrous tissue filling up the gap. Signs of incipient osteogenesis were found on one defect margin adjacent to the former plate location. In contrast, samples in the rhBMP2 group showed extended bone formation within the defect. Lamellar bone in cortical regions and woven bone in the medullary region predominated the histological sections. Samples in the BMP2/7 group showed distinctive callus formation featuring extended osteogenic areas and cartilaginous tissues within the defect. Sufficient bony bridging was not achieved in any specimen. Samples in the PEI_BMP2/ 7 group displayed no signs of bone formation. The defect was filled up with loose fibrous tissue. Osteogenic or chondrogenic precursor cells were absent.
Discussion
We assessed the effects of PEI-based cationic polymers and fibrin GAMs on passive gene transfer of BMP2 and BMP7 plasmids in a femoral nonunion rat model. The main finding of the study was a detrimental effect of the cationic transfection reagent on union rate and bone formation in vivo. Coadministration of cationic polymer for transfection in fibrin GAMs failed to enhanced the therapeutic effect in the experiments. In the PEI_BMP2/7 group, all six femurs showed atrophic nonunions (Fig. 2) . Bone volume in this group was significantly decreased compared with animals treated with BMP2/7 plasmids without cationic polymer (Fig. 3) . Histological sections showed absence of chondrogenic or osteogenic cells (Fig. 4d) . On one hand, this finding is remarkable, as previous studies show beneficial effects of addit i o na l r e a ge n t s s uc h a s l i p o s o m es [ 19 , 2 0 ] or polyethylenimine-based cationic polymers on BMP gene delivery and bone regeneration [19, 20, 27, 28] . Administration of a BMP2 plasmid in combination with lipoplexes increased bone formation and osseointegration in rat and pig models [19, 20] . On the other hand, it is well established that liposomal and cationic reagents exhibit cytotoxic effects in a dose- Fig. 2 Union rate at 4 weeks following treatment of a 3.8-mm critical-size femoral defect (%). Black and grey areas represent unions and narrow unions, respectively. Black and white striped and white areas represent oligotrophic and atrophic nonunions, respectively ). *P<0.05, ** p<0.01. Data are presented as median±interquartile range dependent manner. In cell cultures, administration of lipoplexes caused cell shrinking, decreased mitosis rates and vacuolisation of the cytoplasm. Beyond that, there is evidence of interaction with the immune-mediated cytokine cascade. In vivo administration of lipoplexes led to local and systemic inflammation. Blood-cell agglutination was caused due to the positive charge of the lipids and resulted in local microinfraction and vascular inflammatory response [17, 18] . In vitro tests overcome this problem by using tumorous cell lines, which are held under optimal conditions. Cell loss due to the cytotoxic effects of lipoplexes or cationic polymers can be accepted in certain cases, especially in vitro where high cell numbers are employed for transfection. In contrast, our two-step surgery model of an atrophic nonunion provides a limited number of osteogenic precursor cells and a situation of compromised vascularisation. It is possible that the negative effects of the addition of cationic polymer in this study are a consequence of the cytotoxic effects of PEI on the limited amount of host progenitor cells required for transgene expression and regeneration in this clinically relevant animal model.
Another important finding of this study is the insignificant therapeutic effect of passive gene transfer when administering exclusive BMP2 and 7 plasmids. Three of nine animals in the BMP2/7 group showed oligotrophic nonunions. Histological sections showed extensive areas of incipient osteogenesis without sufficient new bone formation (Fig. 4c) . There was, however, a tendency of increased bone volume in the BMP2/7 group compared with the negative control (FIBRIN group). Nevertheless, inconsistent results due to single outliers failed to show statistically significant differences. This insignificant therapeutic effect was found in numerous studies, which demonstrate nonviral gene transfer as a safe but relative inefficient strategy to increase bone growth [10, 12, 13] . The results of our study emphasise the importance of promoting nonviral gene transfer by alternative methods. Currently, sonoporation or electroporation seem to be the most promising strategies in terms of safety, efficacy and minimal invasiveness [9, [29] [30] [31] . Further studies are needed to clarify whether those strategies are capable of increasing bone growth in a clinically relevant segmental bone-defect model. As a positive control, animals in the rhBMP2 group were treated by application of recombinant growth factor. Not surprisingly, animals showed increased bone volume compared with the FIBRIN and PEI_BMP2/7 groups. As a consequence, osseous, as well as narrow, unions occurred in two of six animals, respectively. Results are supported by a previous study [32] .
In conclusion, the addition of PEI-based cationic polymers to fibrin GAMs failed to promote nonviral gene transfer of BMP2/7 plasmids in this study. Application of BMP2/7 plasmids in fibrin GAMs without cationic polymer lead to variable results in bone volume without sufficient new bone formation to bridge the femoral critical size defect. It indicates a potential advantage of delivering BMP2 and 7 transgenes in fibrin gels for tissue regeneration if enhanced by methods such as the recently developed matrix-assisted sonoporation [33] or methods without application of biomaterials that rely only on physical stimuli for gene delivery, such as sonoporation or electroporation [9, 31] .
